Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Multi-center Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer

NCT07550842 is registered in ClinicalTrials.gov with Shanghai Best-Link Bioscience, LLC as lead sponsor.

NCT NCT07550842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07550842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Multi-center Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
Lead sponsor
Shanghai Best-Link Bioscience, LLC
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 16, 2026
Completion date
August 18, 2028
Enrollment
33 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

small cell carcinoma of lung